Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer.

Journal: Journal of pharmaceutical health care and sciences
Published Date: Mar 2, 2015

Abstract

BACKGROUND: Crizotinib, an ATP-competitive receptor tyrosine kinase inhibitor of both anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor, commonly causes several adverse events (AEs). The clinical utility of measuring the plasma concentration of crizotinib in patients with non-small-cell lung cancer (NSCLC) has not been fully elucidated. The aim of this study was to evaluate the variability in the crizotinib trough concentration and its relationship with the occurrence of AEs in NSCLC patients.

Authors

  • Yasuko Kurata
    Department of Pharmacy, Okayama University Hospital, Okayama, 700-8558 Japan.
  • Narumi Miyauchi
    Department of Oncology Pharmaceutical Care & Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 700-8530 Japan.
  • Manabu Suno
    Department of Oncology Pharmaceutical Care & Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 700-8530 Japan.
  • Takahiro Ito
    Department of Oncology Pharmaceutical Care & Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 700-8530 Japan.
  • Toshiaki Sendo
    Department of Pharmacy, Okayama University Hospital, Okayama, 700-8558 Japan.
  • Katsuyuki Kiura
    Department of Allergy and Respiratory, Okayama University Hospital, Okayama, 700-8558 Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals